Drugs / FluMist
FluMist
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Fluenz | — | 2011-01-27 | europa.eu ↗ |
Trials 73 · started per year
today
EU approved 2011
1
1
4
7
7
1
2
4
4
1
2
3
3
2
7
6
3
2
2
1
1
2
1
5
1
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05921448 | May 2025 → Jul 2026 overdue | influenza | Copenhagen Respiratory Research | Active not recruiting | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT05056519 | Sep → Dec 2021 | — | Changchun BCHT Biotechnology Co. | Unknown | No outcome recorded |
| Phase 1 | NCT03453801 | Sep 2014 → Jan 2019 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT01674205 | Sep 2012 → Jun 2013 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00906750 | Oct 2008 → Jul 2011 | cancer | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00231907 | Sep 2005 → Mar 2007 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00192348 | May → Dec 2002 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01591473 | Apr 2012 → Sep 2014 | influenza | AIM ImmunoTech Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01248208 | Sep 2010 → Sep 2011 | food allergy | Walter Reed Army Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00091702 | ? → Jan 2006 | HIV infectious disease, influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT01181323 | Sep 2011 → May 2013 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00461981 | May → Dec 2007 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00344305 | May → Jul 2006 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192179 | Jun → Jul 2003 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192166 | Oct 2002 → Mar 2003 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192387 | Sep → Dec 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192322 | Sep → Dec 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192309 | Sep → Dec 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192153 | Jul → Oct 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192270 | Oct 2000 → Jan 2001 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 317 trials | ||||||
| Phase 3 | NCT07133802 | Aug 2025 → Mar 2026 overdue | — | Changchun BCHT Biotechnology Co. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT02964065 | Nov 2016 → Aug 2017 | influenza | Changchun BCHT Biotechnology Co. | Completed | No outcome recorded |
| Phase 3 | NCT00325481 | Jun → Dec 2006 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00125944 | Jul 2005 → Jan 2006 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00128167 | Oct 2004 → Dec 2005 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192257 | Oct 2002 → May 2003 | asthma | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192205 | Oct 2002 → Jun 2003 | respiratory tract infectious disorder | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192413 | Mar → Nov 2002 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192400 | Mar → Nov 2002 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192374 | Feb → Nov 2002 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192426 | Sep → Dec 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00217230 | Apr → Nov 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192231 | Apr → Jun 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192192 | Nov → Dec 2000 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192283 | Sep 2000 → Apr 2002 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192244 | Sep 2000 → Oct 2002 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192361 | Nov 1999 → ? | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 428 trials | ||||||
| Phase 4 | NCT07093281 | Feb → Apr 2026 overdue | — | University of Maryland, Baltimore | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07240922 | Oct 2025 → Oct 2030 expected | influenza | The University of Hong Kong | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07177417 | Sep 2025 → Sep 2026 expected | — | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT06501963 | Oct 2024 → Apr 2025 | influenza | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT04164212 | Sep 2020 → Jan 2026 | influenza | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT03884296 | Apr 2019 → Nov 2023 | influenza | Stanford University | Withdrawn | No outcome recorded |
| Phase 4 | NCT03600428 | Oct 2018 → Mar 2020 | childhood onset asthma, influenza, vaccinia | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02866942 | Oct 2016 → Mar 2017 | asthma | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT02549365 | Oct 2015 → Apr 2016 | — | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT03023709 | Sep → Dec 2015 | influenza | Stanford University | Terminated | No outcome recorded |
| Phase 4 | NCT03028987 | Nov 2014 → Nov 2015 | influenza | Stanford University | Terminated | No outcome recorded |
| Phase 4 | NCT03028974 | Sep 2014 → Nov 2017 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT02111512 | Sep 2014 → Feb 2015 | food allergy | University Hospital Southampton NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT02143882 | Sep 2014 → Mar 2017 | — | Public Health England | Completed | No outcome recorded |
| Phase 4 | NCT03023553 | Dec 2012 → Feb 2013 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03023683 | Oct → Nov 2012 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT01933048 | Sep 2012 → Oct 2013 | influenza | Henry M. Jackson Foundation for the Advancement of Military Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02141581 | Aug 2011 → Dec 2014 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03020498 | Sep 2010 → Dec 2011 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT01194297 | Aug 2010 → May 2012 | influenza | University of Rochester | Terminated | No outcome recorded |
| Phase 4 | NCT01987349 | Sep 2009 → Jan 2010 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT02133781 | Jul → Dec 2009 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03020472 | Nov 2008 → Jan 2009 | influenza | Stanford University | Terminated | No outcome recorded |
| Phase 4 | NCT00385281 | Oct 2006 → Apr 2007 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT00138385 | Aug 2005 → Jun 2007 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT00192218 | Oct 2004 → Apr 2005 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 4 | NCT00138294 | Oct 1998 → Jun 2010 | influenza | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00138281 | ? → Nov 2005 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT06620185 | Apr 2025 → Jul 2026 overdue | influenza | Imperial College London | Recruiting | No outcome recorded |
| — | NCT05290792 | Dec 2021 → Oct 2022 | influenza | Emily McDonald | Completed | No outcome recorded |
| — | NCT04110366 | Jun 2018 → Apr 2019 | influenza | Imperial College Healthcare NHS Trust | Completed | No outcome recorded |
| — | NCT02642237 | Dec 2015 → Jan 2017 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT01938170 | Sep 2014 → Apr 2015 | influenza | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT01866540 | Oct 2012 → Dec 2025 overdue | tonsillitis | University of Bergen | Active not recruiting | No outcome recorded |
| — | NCT01673425 | Sep → Dec 2012 | influenza | National Center for Occupational Health and Infection Control | Terminated | No outcome recorded |
| — | NCT01044095 | Nov 2009 → Jul 2010 | influenza | Armed Forces Research Institute of Medical Sciences, Thailand | Completed | No outcome recorded |
Also used as a comparator or background therapy in 16 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01545349 Background | Feb 2012 → May 2013 | influenza | Patricia L. Hibberd | Completed | No outcome recorded |
| Phase 1 | NCT00620412 Comparator | Sep 2007 → Jun 2008 | — | Tufts Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00112112 Comparator | Aug 2005 → Mar 2008 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT00224783 Comparator | Aug → Sep 2002 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05284851 Comparator | Apr → May 2022 | — | Changchun BCHT Biotechnology Co. | Unknown | No outcome recorded |
| Phase 2 | NCT00480155 Comparator | May → Dec 2007 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00111579 Comparator | May 2005 → Jan 2006 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00192127 Comparator | Aug 2004 → Feb 2005 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192335 Comparator | Jul 2004 → Feb 2005 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192491 Comparator | Dec 2000 → Sep 2003 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT03982069 Comparator | Sep 2019 → Dec 2020 | influenza | Richard Zimmerman MD | Completed | No outcome recorded |
| Phase 4 | NCT01653015 Comparator | Nov 2012 → Jun 2015 | influenza | McMaster University | Completed | No outcome recorded |
| Phase 4 | NCT03101462 Comparator | Feb → May 2011 | influenza | St. Louis University | Completed | No outcome recorded |
| Phase 4 | NCT01246999 Comparator | Oct 2010 → Jan 2013 | influenza | University of Rochester | Completed | No outcome recorded |
| Phase 4 | NCT00538512 Comparator | Sep 2007 → May 2008 | influenza | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT00192140 Comparator | Jun → Oct 2004 | influenza | MedImmune LLC | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-20 | AstraZeneca | FluMist approved for self-administration in the US astrazeneca.com ↗ |
| 2023-10-24 | AstraZeneca | US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FluMist Quadrivalent astrazeneca.com ↗ |
| 2015-09-02 | Daiichi Sankyo | Daiichi Sankyo Enters License Agreement with AstraZeneca for Development and Commercialization of FluMist in Japan daiichisankyo.com ↗ |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 92 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FluMist | “Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.” NCT03884296 ↗43“A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study.” NCT00344305 ↗ “Intranasal live attenuated influenza vaccine (LAIV; trade name FluMist/Fluenz-Tetra, manufactured by AstraZeneca/Medimmune)” NCT04110366 ↗ “Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.” NCT01181323 ↗ “0.2mL nasal spray live attenuated influenza vaccine (FluMist, AstraZeneca)” NCT07240922 ↗ |
| Known as | 2012-2013 trivalent seasonal live attenuated influenza vaccine | “2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)” NCT01674205 ↗ |
| Known as | CAIV-T | “trivalent live-attenuated influenza vaccine (CAIV-T)” PMID 17395338 ↗ Mar 200723 |
| Known as | Cold-adapted influenza vaccine trivalent | “Cold-adapted influenza vaccine trivalent (CAIV-T)” NCT00192179 ↗ |
| Known as | Cold-adapted influenza vaccine trivalent (CAIV-T) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00192413 ↗ |
| Known as | FLUENZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01866540 ↗ |
| Known as | Fluenz-Tetra | “Intranasal live attenuated influenza vaccine (LAIV; trade name FluMist/Fluenz-Tetra, manufactured by AstraZeneca/Medimmune)” NCT04110366 ↗ |
| Known as | FluMist Quadrivalent | “FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray” NCT03028974 ↗ |
| Known as | Flumist Quadrivalent Nasal Product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04164212 ↗ |
| Known as | FluMist Seasonal Trivalent Live Attenuated Intranasal Vaccine | “MedImmune, which also provided FluMist Seasonal Trivalent Live Attenuated Intranasal Vaccine for use in the trial.” PMID 23555741 ↗ Mar 2013 |
| Known as | FluMistTM | “Influenza Virus Vaccine Live, Intranasal FluMistTM, a live trivalent nasally administered vaccine” NCT00385281 ↗ |
| Known as | Influenza Virus Vaccine Live | “FluMist, Influenza Virus Vaccine Live” NCT00461981 ↗ |
| Known as | Influenza Virus Vaccine Live, Intranasal | “Influenza Virus Vaccine Live, Intranasal FluMistTM, a live trivalent nasally administered vaccine” NCT00385281 ↗ |
| Known as | Influenza Virus Vaccine, Trivalent, Type A&B, Live, Cold-Adapted | “Influenza Virus Vaccine, Trivalent, Type A&B, Live, Cold-Adapted (CAIV-T)” NCT00192257 ↗1“Influenza Virus Vaccine, Trivalent, Type A&B, Live, Cold-Adapted (CAIV-T)” NCT00192205 ↗ |
| Known as | Influenza Virus Vaccine, Trivalent, Types A & B Live Cold-Adapted Liquid Formulation | “Influenza Virus Vaccine, Trivalent, Types A & B Live Cold-Adapted Liquid Formulation (CAIV-T)” NCT00192179 ↗ |
| Known as | Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted | “A Randomized, Double-Blind Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted...” NCT00192361 ↗2“A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted...” NCT00192348 ↗ “Influenza Virus Vaccine, Trivalent, Types A & B,Live, Cold-Adapted (CAIV-T)” NCT00192374 ↗ |
| Known as | Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) | “Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T)” NCT00192244 ↗ |
| Known as | influenza virus vaccine, trivalent, types A and B, live cold-adapted liquid | “influenza virus vaccine, trivalent, types A and B, live cold-adapted liquid (CAIV-T)” NCT00192348 ↗ |
| Known as | LAIV | “A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years” NCT07133802 ↗6“Live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) are available for children.” PMID 25165161 ↗ Aug 2014 “0.2 ml of Live attenuated influenza vaccine (LAIV), Flumist® given intranasally (IN)” NCT01181323 ↗ “A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine)” NCT02866942 ↗ “Administration of Live attenuated influenza vaccine (LAIV)” NCT02111512 ↗ “live attenuated influenza vaccine (LAIV or FluMist)” NCT00138294 ↗ “Live-Attenuated influenza Vaccine(LAIV)” NCT02964065 ↗ |
| Known as | LAIV4 | “Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.” NCT03023709 ↗1“quadrivalent live attenuated influenza vaccine (LAIV4)” NCT03600428 ↗ |
| Known as | LAVI | “Live Attenuated freeze-dried Influenza Vaccine has been licensed for use in 2020 (Approval No.S20200002), the sponsor of this research submitted an new application for non...” NCT05056519 ↗ |
| Known as | Live attenuated influenza vaccine | “Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination...” NCT00138294 ↗ |
| Known as | Live Attenuated Intranasal Vaccine | “A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine) has recently been approved” NCT02111512 ↗1“A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine)” NCT02866942 ↗ |
| Known as | Trivalent Cold-Adapted Influenza Vaccine | “Trivalent Cold-Adapted Influenza Vaccine (CAIV-T)” NCT00111579 ↗ |
| Modality | Vaccine | “FluMist, a cold-adapted live attenuated influenza vaccine, is both immunogenic and effective in HIV infected children” NCT00091702 ↗ |
| Route | Intranasal | “will be administered intranasally” NCT00111579 ↗ |